The predictive relationship of food-specific serum IgE concentrations to challenge outcomes for egg and milk varies by patient age

2007 ◽  
Vol 119 (5) ◽  
pp. 1272-1274 ◽  
Author(s):  
Takatsugu Komata ◽  
Lars Söderström ◽  
Magnus P. Borres ◽  
Hiroshi Tachimoto ◽  
Motohiro Ebisawa
Keyword(s):  
Patient Age ◽  
Serum Ige ◽  
Specific Serum ◽  
Patient Âgé ◽  
Relationship Of ◽  
Predictive Relationship

scholarly journals Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19

2020 ◽  
Author(s):  
Carlo Cervia ◽  
Jakob Nilsson ◽  
Yves Zurbuchen ◽  
Alan Valaperti ◽  
Jens Schreiner ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Healthcare Workers ◽  
Immunoglobulin A ◽  
Antibody Responses ◽  
Patient Age ◽  
Mild Disease ◽  
Specific Serum ◽  
Patient Âgé ◽  
Serum Iga ◽  
Very High

AbstractBackgroundInfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes an acute illness termed coronavirus disease 2019 (COVID-19). Humoral immune responses likely play an important role in containing SARS-CoV-2, however, the determinants of SARS-CoV-2-specific antibody responses are unclear.MethodsUsing immunoassays specific for the SARS-CoV-2 spike protein, we determined SARS-CoV-2-specific immunoglobulin A (IgA) and immunoglobulin G (IgG) in sera and mucosal fluids of two cohorts, including patients with quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR)-confirmed SARS-CoV-2 infection (n = 56; median age 61 years) with mild versus severe COVID-19, and SARS-CoV-2-exposed healthcare workers (n = 109; median age 36 years) with or without symptoms and tested negative or positive by RT-qPCR.FindingsOn average, SARS-CoV-2-specific serum IgA titers in mild COVID-19 cases became positive eight days after symptom onset and were often transient, whereas serum IgG levels remained negative or reached positive values 9–10 days after symptom onset. Conversely, patients with severe COVID-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers as a function of duration since symptom onset, independent of patient age and comorbidities. Very high levels of SARS-CoV-2-specific serum IgA correlated with severe acute respiratory distress syndrome (ARDS). Interestingly, some of the SARS-CoV-2-exposed healthcare workers with negative SARS-CoV-2-specific IgA and IgG serum titers had detectable SARS-CoV-2-specific IgA antibodies in their nasal fluids and tears. Moreover, SARS-CoV-2-specific IgA levels in nasal fluids of these healthcare workers were inversely correlated with patient age.InterpretationThese data show that systemic IgA and IgG production against SARS-CoV-2 develops mainly in severe COVID-19, with very high IgA levels seen in patients with severe ARDS, whereas mild disease may be associated with transient serum titers of SARS-CoV-2-specific antibodies but stimulate mucosal SARS-CoV-2-specific IgA secretion. The findings suggest four grades of antibody responses dependent on COVID-19 severity.

Relationship of Myoma Cell Size and Menopausal Status in Small Uterine Leiomyomas

2000 ◽  
Vol 124 (10) ◽  
pp. 1448-1453
Author(s):  
Stewart F. Cramer ◽  
Carol Marchetti ◽  
Joshua Freedman ◽  
Aasim Padela
Keyword(s):  
Cell Size ◽  
Menopausal Status ◽  
Premenopausal Women ◽  
Uterine Leiomyomas ◽  
Growth Potential ◽  
Patient Age ◽  
Patient Âgé ◽  
Mutation Theory ◽  
Postmenopausal Status ◽  
Relationship Of

Abstract Context.—Although myomas shrink after menopause, the cellular mechanism for this phenomenon has received little attention. It was recently demonstrated that fibrous degeneration is significantly associated with postmenopausal status in both small and large myomas. Objective.—The purpose of the present study was to evaluate whether reduction in myoma cell size is also associated with postmenopausal status in small myomas. Design.—Tumor size and patient age have also been related to fibrous degeneration in small (<1 cm) myomas. Therefore, in the present study, 10 pairs of premenopausal and postmenopausal small myomas were matched within 3 years for patient age, within 1 mm for size, and within 1 grade for degree of fibrous degeneration. Most of the women were in their 50s, the decade during which postmenopausal fibrous degeneration in small myomas is most prevalent. Myoma cell size was derived by morphometric evaluation of relative myoma cell area (correcting for percentage of stroma, as measured by point counting) and by direct counting of the number of myoma cells per unit area in trichrome-stained sections. Results.—Small myomas from postmenopausal women had significantly (P < .05) smaller cell sizes than did size-matched myomas from age-matched premenopausal women. Myoma cell sizes and nucleus-cell (N/C) ratios were highly variable, especially in premenopausal myomas. Conclusions.—Reduction in myoma cell size is significantly associated with postmenopausal status in small uterine leiomyomas and may be an important mechanism for postmenopausal shrinkage of myomas. In addition, the high variability of myoma cell size and N/C ratio may further support the somatic mutation theory (ie, the theory that diverse mutations may account not only for variations in the growth potential of uterine myomas, but also for variations in their cellular details).

scholarly journals A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype

Blood ◽  
1982 ◽  
Vol 59 (5) ◽  
pp. 1013-1022 ◽  
Author(s):  
JD Rowley ◽  
G Alimena ◽  
OM Garson ◽  
A Hagemeijer ◽  
F Mitelman ◽  
...  
Keyword(s):  
Collaborative Study ◽  
Morphological Type ◽  
Acute Nonlymphocytic Leukemia ◽  
Patient Age ◽  
Patient Âgé ◽  
Relationship Of ◽  
The Relationship

Community use of anthracyclines for adjuvant HER2-positive breast cancer (BC).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11609-e11609
Author(s):  
Akhil Kumar ◽  
Marc L. Fishman ◽  
William S. Shimp ◽  
Laura Rose Bobolts ◽  
James Edward Krook ◽  
...  
Keyword(s):  
The Elderly ◽  
Cardiac Events ◽  
Her2 Positive ◽  
Chi Square ◽  
Adjuvant Trastuzumab ◽  
Patient Age ◽  
Patient Âgé ◽  
Chi Square Analysis ◽  
Improvement In Survival ◽  
Relationship Of

e11609 Background: Anthracyclines remain among the most active agents for the treatment of BC. NSABP B-31, NCCTG N9831 and HERA, each employing anthracyclines followed by trastuzumab in adjuvant HER2+ BC, demonstrated significant reduction in the risk of recurrence and improvement in survival. A fourth study, BCIRG-006, compared a non-anthracycline containing regimen, TCH, to an anthracycline based regimen, AC-TH. Both arms had similar overall survival, but there was a higher incidence of cardiac events in patients who received anthracycline. HER2-analyses in randomized adjuvant trials, in the pre-trastuzumab era, comparing anthracycline with non-anthracycline chemotherapy regimens, show that HER2+ BC derives greater benefit from anthracycline use. TOP2A coamplification, which occurs in 35% of HER2-positive patients, has shown a direct association with anthracycline benefit in several studies. We investigate and report, herein, the ways in which community oncologists are currently treating these patients. Methods: All treatment requests for adjuvant trastuzumab were examined, from 2009 through 2012. Chi-square analysis at 0.05α was used to test for interaction of age group to type of treatment. Results: During this span, oncologists requested adjuvant trastuzumab for 121 patients. In 10% (12/121) of patients, adjuvant trastuzumab alone, without chemotherapy and with or without hormonal therapy, was requested. Among patients who also received adjuvant chemotherapy (109), 35% (38/109), received anthracyclines. There was no relationship of anthracycline-usage with BC stage (data not shown) or patient age (Chi Sq p = 0.73). Adjuvant trastuzumab, without chemotherapy, was requested more often for the elderly (20% versus 4%; Chi Sq p = 0.003). Conclusions: Anthracyclines are utilized in adjuvant HER2+ BC in only about a third of patients, regardless of BC stage or patient age. The availability of a reliable, inexpensive, and convenient test to predict which patients are most likely to benefit from anthracyclines, over other options, would be useful. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document